Jazz Pharmaceuticals PLC (JAZZ) stock is soaring 5.01% in Thursday's intraday trading session, buoyed by positive analyst ratings and price target adjustments. The pharmaceutical company's shares are gaining momentum as Wall Street analysts express confidence in its future prospects.

Deutsche Bank has adjusted its price target for Jazz Pharmaceuticals from $152 to $154, while maintaining a Buy rating on the stock. This upward revision suggests the bank's analysts see potential for further growth in JAZZ shares. Additionally, Robert W. Baird reiterated its Buy rating for the company, setting a price target of $160.00, which represents a significant premium to the current trading price.

The bullish sentiment from multiple analysts is likely driving investor optimism, contributing to today's substantial stock price increase. According to FactSet, Jazz Pharmaceuticals has an average rating of Buy among polled analysts, with a mean price target of $182.44. This consensus view indicates that Wall Street generally sees considerable upside potential for JAZZ stock, which may be encouraging investors to bid up the shares in today's trading session.